Episode 2032
2032: hVIVO Interview - CEO Mo Khan on New RSV Human Challenge Trial & Company Growth
The Vox Markets Podcast · Vox Markets Podcast
February 3, 20258m 42s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this exclusive interview, hVIVO CEO Mo Khan discusses the company’s latest human challenge trial contract with Inhalon Biopharma, testing a next-generation mucosal RSV antiviral. Mo addresses industry speculation around RSV trials, explains why RSV antivirals remain a key growth area, and shares insights on hVIVO’s strong sales pipeline conversion, with this being their fourth new study announcement in under two months. He also provides a quick update on the recent CRS acquisition and what’s next for the company.